Exercise improves cardiorespiratory fitness and quality of life in patients with hypertrophic cardiomyopathyExercise improves heart health and fitness for HCM patients

This meta-analysis synthesized data from 9,702 patients diagnosed with hypertrophic cardiomyopathy (HCM) to evaluate the impact of exercise on various clinical and physiological outcomes. The study design integrated results from a mix of randomized controlled trials and observational studies to provide a comprehensive overview of how structured exercise affects this specific patient population.

The primary focus was on cardiorespiratory fitness as the main outcome measure. Results indicated that exercise is associated with significant improvements in peak oxygen consumption (peak VO). Specifically, the mean difference (MD) for peak VO was 1.78 mL*kg*min (95% CI [0.98, 2.59]; p < 0.01). Additionally, VO at an anaerobic threshold showed a significant increase with an MD of 1.27 mL*kg*min (95% CI [0.34, 2.20]; p < 0.01).

Secondary outcomes provided further insight into the physiological and lifestyle impacts of exercise in HCM patients. The analysis reported a reduction in body mass index (BMI) with an MD of -0.67 kg/m (95% CI [-1.17, -0.18]; p < 0.01). Regarding cardiac structure, there was a statistically significant decrease in left ventricular wall thickness by an MD of -0.56 mm (95% CI [-1.01, -0.11]; p = 0.01). Furthermore, the quality of life physical factor showed a substantial improvement with a standardized mean difference (SMD) of 0.66 (95% CI [0.34, 0.97]; p < 0.01).

Regarding mortality, the meta-analysis reported a decreased incidence of all-cause mortality with a relative risk (RR) of 0.71 (95% CI [0.60, 0.85]; p < 0.01). However, it is critical to note that this specific finding regarding mortality was primarily driven by observational studies rather than controlled trials.

Safety and tolerability data indicated no increase in the risk of arrhythmias for patients undergoing exercise interventions. Specific rates for adverse events, serious adverse events, or study discontinuations were not reported in the included data. The findings suggest that structured exercise is generally well-tolerated within this population.

When comparing these results to previous literature, the evidence supports the inclusion of exercise as a viable component of management for HCM patients seeking to improve fitness and quality of life. However, clinicians must interpret the mortality reduction with caution due to the reliance on observational data for that specific metric. The study highlights several limitations, most notably the need for larger randomized controlled trials to confirm the findings derived from mixed study designs.

Clinical implications suggest that structured exercise interventions are safe and associated with improvements in cardiorespiratory fitness, left ventricular wall thickness, body mass index, and quality of life physical factors in patients with HCM. While the data is promising, questions remain regarding the optimal intensity and duration of these programs to maximize benefits while ensuring safety. Further large-scale randomized trials are necessary to provide higher certainty for mortality outcomes.